News Image

Should Quality Investors Include NYSE:NVO in Their Portfolio?

By Mill Chart

Last update: May 16, 2024

In this article we will dive into NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) as a possible candidate for quality investing. Investors should always do their own research, but we noticed NOVO-NORDISK A/S-SPONS ADR showing up in our Caviar Cruise quality screen, which makes it worth to investigate a bit more.

Key Considerations for Quality Investors.

  • NOVO-NORDISK A/S-SPONS ADR has achieved substantial revenue growth over the past 5 years, with a 15.74% increase. This signifies the company's ability to successfully capture market opportunities and generate sustained revenue growth.
  • NOVO-NORDISK A/S-SPONS ADR demonstrates impressive performance in terms of ROIC excluding cash and goodwill, with a 136.0% ratio. This highlights the company's efficient utilization of capital and its focus on maximizing returns for investors.
  • NOVO-NORDISK A/S-SPONS ADR maintains a healthy Debt/Free Cash Flow Ratio of 0.54, indicating a strong financial position and prudent debt management. This ratio suggests the company has sufficient free cash flow to cover its debt obligations and highlights its ability to generate cash from operations.
  • The Profit Quality (5-year) of NOVO-NORDISK A/S-SPONS ADR stands at 92.21%, highlighting its ability to consistently generate reliable profits. This metric underscores the company's strong business fundamentals and reinforces its position as a financially stable entity.
  • NOVO-NORDISK A/S-SPONS ADR has consistently achieved strong EBIT growth over the past 5 years, with a 17.25% increase. This underscores the company's effective management of its operating income and suggests a positive outlook for future profitability.
  • With EBIT 5-year growth outpacing its Revenue 5-year growth, NOVO-NORDISK A/S-SPONS ADR showcases its effective cost management and enhanced operational performance. This suggests the company's ability to generate higher earnings from its revenue streams.

Fundamental Analysis Observations

ChartMill assigns a Fundamental Rating to every stock. This score, ranging from 0 to 10, is updated daily and is determined by evaluating multiple fundamental indicators and properties.

We assign a fundamental rating of 7 out of 10 to NVO. NVO was compared to 197 industry peers in the Pharmaceuticals industry. Both the health and profitability get an excellent rating, making NVO a very profitable company, without any liquidiy or solvency issues. NVO is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one! This makes NVO very considerable for growth and quality investing!

Check the latest full fundamental report of NVO for a complete fundamental analysis.

More ideas for quality investing can be found on ChartMill in our Caviar Cruise screen.


This article should in no way be interpreted as advice in any way. The article is based on the observed metrics at the time of writing, but you should always make your own analysis and trade or invest at your own responsibility.



NYSE:NVO (5/29/2024, 7:21:04 PM)

Premarket: 134.05 +1.37 (+1.03%)


-1.4 (-1.04%)

NVO News

News Image2 days ago - The Motley FoolA New Name in Weight Loss Drugs

Novo Nordisk and Eli Lilly have soared on the popularity of GLP-1 weight loss drugs. Now Hims & Hers is trying to get in on the action with a more available and affordable option.

News Image2 days ago - InvestorPlaceOZEM ETF: 7 Things to Know About the New Roundhill GLP-1 & Weight Loss ETF

As weight loss drugs are gaining popularity Roundhill GLP 1 And Weight Loss ETF (OZEM) has launched as anew way to invest in them.

News Image2 days ago - The Motley FoolSoaring Eli Lilly Stock Could Climb Another 24% According to a Wall Street Analyst. Is the Stock a Buy Now?

Plowing $9 billion into a manufacturing facility could help a successful tirzepatide launch reach new heights.

News Image3 days ago - InvestorPlaceThe Penny Stock Prophecy: 3 Overlooked Stocks Primed to Pop

Overlooked penny stocks are the path to outsized gains and these shares seem to fit the bill at the moment.

News Image3 days ago - InvestorPlace7 Biotech Stocks to Put on Your Breakthrough Radar

Although biotech stocks can present volatility risks due to its feast-or-famine nature, their narrative offers permanent relevance.

News Image4 days ago - The Motley FoolAmgen's Catching Up to Novo Nordisk and Eli Lilly. Should You Buy It?

The gold rush for obesity medications just got a bit more intense.

News Image5 days ago - The Motley FoolWhere Will Novo Nordisk Be in 10 Years?

Will Novo Nordisk top $1 trillion in market value?

News Image5 days ago - The Motley Fool3 High-Flying Stocks That Could Soar Even More

The momentum should continue for Eli Lilly, Novo Nordisk, and Vertex Pharmaceuticals.

News Image6 days ago - InvestorPlaceStocks to Buy: 7 Undeniable Dow Darlings to Pile Into Now

Most Dow stocks are strong investments but these 7 stand out at the moment as the macroenvironment trends positive again.

News Image7 days ago - InvestorPlaceMove Over Ozempic! 3 New GLP-1 Drugs and Products Coming Soon.

The search for the next GLP-1 drugs that will be blockbuster winners during the next market cycle is on, and here are three contenders.

News Image14 days ago - ChartmillShould Quality Investors Include NYSE:NVO in Their Portfolio?

Is NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) suited for quality investing?

NVO Links
Follow us for more